AstraZeneca Will Validate siRNA Delivery Technology For MDRNA In Shanghai Innovation Center
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Bothell, Washington-headquartered MDRNA announced recently that the company will collaborate with AstraZeneca to validate MDRNA's small interfering RNA (siRNA) technology for systemic delivery in hepatocellular carcinoma, one of the company's preclinical oncology programs
You may also be interested in...
China Leads Pharmaceutical Growth In 2009: Asia Pharma R&D Leaders
SHANGHAI - While China's most influential meeting - the eleventh National People's Congress of China - prepares to open its third session in Beijng March 5, pharma R&D leaders gathered in Shanghai to discuss the future of the pharmaceutical industry
Renamed Nastech Turns To RNAi
Company to divest intranasal program rather than spin out.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).